Linerixibat is a small molecule commercialized by GSK, with a leading Phase III program in Pruritus. According to Globaldata, it is involved in 15 clinical trials, of which 12 were completed, and 3 ...

With that in mind, GSK is partnering with developer Reef and investor UBS Asset Management to build a 1.4M SF, £900M life ...

The data include an interim look at the dose-escalation portion of a phase 2 trial assessing the adenosine A2A receptor ...

Updated results from the DREAMM-7 trial support the use of belantamab mafodotin plus bortezomib and dexamethasone “as a potential new standard of care,” according to Vania Hungria, MD, PhD.

Shares of GSK PLC GSK inched down 0.48% to £13.34 Thursday, on what proved to be an all-around positive trading session for the stock market, with the FTSE 100 Index UKX rising 0.12% to 8,311.76.

The incidence and prevalence of genital herpes simplex virus (HSV) type 1 and 2 infections are high worldwide, contr ...

Shares of AnaptysBio, Inc. ANAB, a clinical-stage biotechnology company, plunged 32.8% on Dec. 11 after it announced that the ...

November 2024 has seen a variety of biotech deals take place to advance therapies across different stages in development.

Jon Smith looks back on some words of wisdom from Warren Buffett about how and where to invest as the market keeps rallying.

The arrest in the slaying of UnitedHealthcare CEO Brian Thompson was the first step to putting his killer behind bars, though ...

A fiver a day seems like a small price to pay for a potentially lucrative second income later in life. But patience and ...

Barclays analyst Emily Field maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.50. The ...